BeiGene Signs a Clinical Trial Agreement with ImmixBio to Evaluate IMX-110 + Tislelizumab in Solid Tumors
Shots:
- ImmixBio to assess the safety- tolerability- and efficacy of IMX-110 in combination with tislelizumab in a P-I/IIa trial in patients with advanced solid tumors
- The novel approach of combining ImmixBio’s tissue specific therapeutics (TSTx) with immunotherapies could expand the population of cancer patients experiencing extended remissions
- The pre-clinical studies showed IMX-110 turns "cold" tumors "hot-" and IMX-110 + murine anti-PD-1 demonstrated extended survival in a genetic mouse model of pancreatic cancer vs multi-drug combinations in the literature showed substantial rationale to combine IMX-110 and tislelizumab
| Ref: PR Newswire | Image: BeiGene
Click here to read the full press release
Tuba was Senior Editor at PharmaShots. She was curious, creative, and passionate about recent updates and innovations in the life sciences industry. She covered Biopharma, MedTech, and Digital health segments. Tuba also had an experience in digital and social media marketing and ran the campaigns independently. She can be contacted at [email protected].
